author-photo

Jill Hallin

Pfizer

20

Papers

988

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Abstract B23: Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257: A prototype selective inhibitor of KRAS G12C

2020 Molecular Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract B30: Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer

2020 Molecular Cancer Research
Show All
- Source
- Cite
- Save
Citations (6)
Abstract LB-098: The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS(G12C) Inhibitor for the Treatment of Cancer.

2020 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (71)
Abstract LB-271: Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257, a novel KRAS G12C mutant selective small molecule inhibitor

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients

2019 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (350)
Abstract C069: The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (4)
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.

2018 ACS Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (28)
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

2018 Cancer Immunology, Immunotherapy
Show All
- Source
- Cite
- Save
Citations (60)
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (71)